@entity5298 ( XXXX ) levels in peri-implant crevicular fluid.

@entity1 @entity2520 @entity548 @entity33 @entity5298 @entity737
BACKGROUND: @entity5298 ( @entity5298 ) is one of the key cytokines in the induction of osteoclastogenesis both in vitro and in vivo. Several reports indicated the presence of sRANKL in gingival crevicular fluid of @entity1 with @entity2520 . OBJECTIVE: To determine the presence of @entity5298 in peri-implant crevicular fluid samples of implants with @entity737 , @entity33 and healthy controls. METHODS: In this study, 40 implants were categorized as clinically healthy, @entity33 and @entity737 according to the clinical and radiographic findings. Filter paper strips were used to collect peri-implant crevicular fluid for 30 seconds in the base of the crevice/pocket. Peri-implant crevicular fluid (PICF) samples were obtained from buccal and lingual aspects of implants. Plaque index, probing depth, gingival index and @entity548 on probing were recorded at six sites per implant. Enzyme-linked immunosorbent assay (ELISA) was performed to determine the PICF levels of sRANKL. RESULTS: There were no statistically significant differences in sRANKL concentration between healthy group, @entity33 and @entity737 (p=0.12). There were also no statistical correlation between the concentration of sRANKL and probing pocket depth (R=0.051, p=0.65), or any of the other clinical regarding (p>0.05). No differences between the mean sRANKL concentration in the buccal and lingual sites were found (p=0.693). CONCLUSION: Our results may suggest that peri-implant crevicular fluid analysis of sRANKL in conjunction with some other osteoclastogenic mediators could be further investigated in further well-designed prospective longitudinal studies on a larger-scale sample size in the evaluation of dental implants.
